CytRx Corporation (NASDAQ:CYTR) and INSYS Therapeutics Inc. (NASDAQ:INSY), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation of the two firms.
Valuation and Earnings
Table 1 demonstrates CytRx Corporation and INSYS Therapeutics Inc.’s top-line revenue, earnings per share and valuation.
Table 2 hightlights the net margins, return on assets and return on equity of the two companies.
CytRx Corporation has a 2.2 beta, while its volatility is 120.00% which is more volatile than Standard Poor’s 500. INSYS Therapeutics Inc.’s 156.00% more volatile than Standard Poor’s 500 which is a result of the 2.56 beta.
CytRx Corporation has a Current Ratio of 3.1 and a Quick Ratio of 3.1. Competitively, INSYS Therapeutics Inc.’s Current Ratio is